Metabolic Biomarkers for Cognitive Ability

OVERVIEW

Georgetown University and Rochester University researchers developed metabolic biomarkers for assessing cognitive health by analyzing metabolite levels in blood samples. This technology offers a proactive approach to identifying individuals at risk of memory impairment, providing early intervention and personalized treatment opportunities.

BACKGROUND

As individuals age, cognitive decline becomes increasingly common, posing significant challenges to quality of life and healthcare systems. Predicting and preventing memory impairment is crucial, yet existing methods often lack precision and accessibility. Plasma Metabolite Profiling revolutionizes cognitive health assessment by leveraging blood-based biomarkers to detect subtle changes associated with future memory decline.

Benefit

• Precise Cognitive Risk Assessment: Metabolic biomarkers for cognitive ability technology enables accurate identification of individuals at risk of memory impairment by analyzing metabolite levels in blood samples.
• Early Intervention Opportunities: By detecting subtle changes in metabolite profiles, this technology provides opportunities for early intervention and personalized treatment plans to mitigate cognitive decline.
• Minimally Invasive Screening: Unlike traditional cognitive assessments, these metabolic biomarkers offer a minimally invasive and cost-effective method for assessing cognitive health, making it accessible to a broader population.

Market Application

• Can be utilized by healthcare providers for routine cognitive health screenings, enhancing preventive care strategies.
• Offers valuable insights into the development of novel therapeutics for cognitive disorders, including Alzheimer's disease.
• Addresses the growing need for effective cognitive health assessment tools in aging populations, supporting healthy aging initiatives.
• Serves as a valuable biomarker tool in clinical trials aimed at evaluating cognitive interventions and treatments.
• Integrates seamlessly into wellness programs to monitor cognitive health and promote proactive lifestyle interventions.

Publications

US Patent No. 11, 280, 797

Mapstone, M. et al.) What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease. Neurobiology of Aging. Mar. 2017, Epub Nov. 21, 2016, vol. 51; pp. 148-155.

Mapstone, M. et al.) Plasma phospholipids identity antecedent memory impairment in older adults. Nature Medicine. Apr. 2014, Epub Mar. 9, 2014, vol. 20, No. 4; pp. 415-418.